Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-24T17:42:10.549Z Has data issue: false hasContentIssue false
  • English
  • Français

Continuing clozapine treatment after a diagnosis of cardiomyopathy

Published online by Cambridge University Press:  09 May 2018

F. Williams ,
F. Lenihan  and
A. Rowe
F. Williams*
Affiliation:
NHS Fife, Learning Disability Service, Lynebank Hospital, Dunfermline, Halbeath, Fife, UK
F. Lenihan
Affiliation:
NHS Lothian, Orchard Clinic, Royal Edinburgh Hospital, Edinburgh, UK
A. Rowe
Affiliation:
Medicines Management Team, NHS Lothian, Edinburgh, UK
*
*Address for correspondence: Dr F. Williams, NHS Fife, Learning Disability Service, Lynebank Hospital, Dunfermline, Halbeath, Fife KY8 4NZ, UK. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

A patient in a medium secure psychiatric unit with a 19-year history of treatment-resistant schizophrenia and violence whose mental illness only responded to clozapine, was noted to have a sustained tachycardia. Echocardiography revealed mild biventricular cardiomyopathy. The patient was not significantly affected by this. Initial recommendation from Cardiology was to consider discontinuation of clozapine. It was decided, however, that the risk of worsening psychosis and resultant violence outweighed the risk of the patient’s relatively mild cardiomyopathy. The patient was commenced on ramipril, and later bisoprolol. The patient no longer requires treatment in a medium secure unit and has remained on clozapine with follow-up from cardiology.

Keywords

Cardiomyopathyclozapineforensicsschizophrenia
Type
Case Report
Information
Irish Journal of Psychological Medicine , Volume 38 , Issue 3 , September 2021 , pp. 227 - 231
Copyright
© College of Psychiatrists of Ireland 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alawami, M, Kenedi, C, Cicovic, A, Muir, A (2012). Echocardiography in the prevention of clozapine induced cardiomyopathy. European Journal of Heart Failure Supplements 11 (Suppl. 1): S27.Google Scholar
Conley, RR (1998). Optimizing treatment with clozapine. Journal of Clinical Psychiatry 59 (Suppl. 3): 44–48.Google ScholarPubMed
Electronic Medicines Compendium (2016). SPC for Zaponex 25mg and 100mg tablets, eMC (http://www.medicines.org.uk/emc/medicine/30938). Accessed 14 March 2016.Google Scholar
Estefanos, M, Swift, R, Bernhardt, LL (2013). Clozapine and cardiomyopathy: a case report. CNS Spectrums 18, 334–335.Google Scholar
Floreani, J, Bastiampillai, T (2008). Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. The Australian and New Zealand Journal of Psychiatry 42, 747–748.Google ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63, 622–629.10.1001/archpsyc.63.6.622CrossRefGoogle ScholarPubMed
Meltzer, HY, Alphs, L, Green, AI, Altamura, AC, Anand, R, Bertoldi, A, Bourgeois, M, Chouinard, G, Islam, MZ, Kane, J, Krishnan, R, Lindenmayer, JP, Potkin, S (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82–91.10.1001/archpsyc.60.1.82CrossRefGoogle Scholar
Merrill, DB, Dec, GW, Goff, DC (2005). Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology 25, 32–41.10.1097/01.jcp.0000150217.51433.9fCrossRefGoogle ScholarPubMed
Newby, DE, Grubb, NR, Bradbury, A (2010). Cardiovascular disease. In Davidson’s Principles and Practice of Medicine 21st Edition (ed. N. R. Colledge, B. R. Walker and S. H. Ralston), pp. 521–640. Churchill Livingstone: Edinburgh.10.1016/B978-0-7020-3085-7.00018-3CrossRefGoogle Scholar
Nissen, T, Wynn, R (2014). The clinical case report: a review of its merits and limitations. BMC Research Notes 7, 264.10.1186/1756-0500-7-264CrossRefGoogle ScholarPubMed
Roh, S, Ahn, DH, Nam, JH, Yang, BH, Lee, BH, Kim, YS (2006). Cardiomyopathy associated with clozapine. Experimental and Clinical Psychopharmacology 14, 94–98.10.1037/1064-1297.14.1.94CrossRefGoogle ScholarPubMed
Rostagno, C, Di Norscia, G, Placidi, GF, Gensini, GF (2008). Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. General Hospital Psychiatry 30, 280–283.10.1016/j.genhosppsych.2007.09.003CrossRefGoogle ScholarPubMed
Sawicke, L, Sturla, S (2008). Potentially lethal cardiac side effects caused by psychiatric drugs. Vertex 19, 387–393.Google ScholarPubMed
Vaddadi, KS, Soosai, E, Vaddadi, G (2003). Low blood selenium concentrations in schizophrenic patients on clozapine. British Journal of Clinical Pharmacology 55, 307–309.10.1046/j.1365-2125.2003.01773.xCrossRefGoogle ScholarPubMed
Wheeler, A, Hymerstone, V, Robinson, G (2009). Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of Psychopharmacology 23, 957–965.CrossRefGoogle ScholarPubMed